StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

by · The Markets Daily

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of Evoke Pharma stock opened at $0.47 on Friday. Evoke Pharma has a 1 year low of $0.40 and a 1 year high of $1.77. The business has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.65. The company has a market capitalization of $4.06 million, a P/E ratio of -0.26 and a beta of 0.38.

Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The business had revenue of $1.74 million during the quarter.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Further Reading